Delving into the Latest Updates on Functional Genetics, Inc. with Synapse

Overview

Aerobiology plays a fundamental role in the transmission of infectious diseases. As infectious disease and infection control practitioners continue employing contemporary techniques (e.g., computational fluid dynamics to study particle flow, polymerase chain reaction methodologies to quantify particle concentrations in various settings, and epidemiology to track the spread of disease), the central variables affecting the airborne transmission of pathogens are becoming better known. This paper reviews many of these aerobiological variables (e.g., particle size, particle type, the duration that particles can remain airborne, the distance that particles can travel, and meteorological and environmental factors), as well as the common origins of these infectious particles. We then review several real-world settings with known difficulties controlling the airborne transmission of infectious particles (e.g., office buildings, healthcare facilities, and commercial airplanes), while detailing the respective measures each of these industries is undertaking in its effort to ameliorate the transmission of airborne infectious diseases.

01 May 2010·Antimicrobial Agents and ChemotherapyQ2 · MEDICINE

Antiviral Activity of a Small-Molecule Inhibitor of Filovirus Infection

Q2 · MEDICINE

Article

Author: Aman, M. Javad ; Warren, Travis K. ; Goldblatt, Michael ; Ruthel, Gordon ; Wells, Jay ; Smith, Mark ; Bavari, Sina ; Warfield, Kelly L. ; Kinch, Michael S. ; Yunus, Abdul S. ; Enterlein, Sven

ABSTRACT There exists an urgent need to develop licensed drugs and vaccines for the treatment or prevention of filovirus infections. FGI-103 is a low-molecular-weight compound that was discovered through an invitro screening assay utilizing a variant of Zaireebolavirus (ZEBOV) that expresses green fluorescent protein. Invitro analyses demonstrated that FGI-103 also exhibits antiviral activity against wild-type ZEBOV and Sudanebolavirus , as well as Marburgvirus (MARV) strains Ci67 and Ravn. Invivo administration of FGI-103 as a single intraperitoneal dose of 10 mg/kg delivered 24 h after infection is sufficient to completely protect mice against a lethal challenge with a mouse-adapted strain of either ZEBOV or MARV-Ravn. In a murine model of ZEBOV infection, delivery of FGI-103 reduces viremia and the viral burden in kidney, liver, and spleen tissues and is associated with subdued and delayed proinflammatory cytokine responses and tissue pathology. Taken together, these results identify a promising antiviral therapeutic candidate for the treatment of filovirus infections.

01 Apr 2010·Analytical and quantitative cytology and histology

Identification of annexin A13 as a regulator of chemotherapy resistance using random homozygous gene perturbation.

Article

Author: Li, Limin ; Kinch, Michael S ; Donahue, Robert ; Goldblatt, Michael ; Reiske, Heinz ; Sui, Baoquan ; Li, Wu-Bo ; Ung-Medoff, Huong

OBJECTIVETo utilize a powerful new technology for target discovery, Random Homozygous Gene Perturbation (RHGP), and to identify novel targets that cause tumor cells to become chemoresistant.STUDY DESIGNRHGP was used to identify and validate genetic changes that cause chemoresistance of tumor cells to Rapamycin.RESULTSA series of targets was identified that allowed tumor cells to survive treatment with Rapamycin. We validated these targets and focused on Annexin A13, a target where decreased expression caused tumor cell insensitivity to Rapamycin. Ectopic overexpression of Annexin A13 was likewise sufficient to sensitize malignant breast cancer cells to treatment with Rapamycin.CONCLUSIONThese findings expand our knowledge of mechanisms that allow tumor cell drug resistance and demonstrate the power of RHGP to identify novel targets and mechanisms.

100 Deals associated with Functional Genetics, Inc.

Login to view more data

100 Translational Medicine associated with Functional Genetics, Inc.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

7

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

FGI-103-723 ( caspase 2 )	Hemorrhagic Fever, Ebola More	Pending
FGI-1011A6 ( TSG101 )	Influenza, Human More	Pending
FGI-110 ( NEDD4 )	Respiratory Tract Infections More	Pending
FGI-104 series	Virus Diseases More	Pending
FGI-106 series (Functional Genetics)	Virus Diseases More	Pending